Enzalutamide treatment for the whole spectrum of CRPC
Crossref DOI link: https://doi.org/10.1038/s41585-018-0090-1
Published Online: 2018-09-21
Published Print: 2018-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhao, Hanson
Freedland, Stephen
Text and Data Mining valid from 2018-09-21
Article History
First Online: 21 September 2018
Competing interests
: S.F. is a consultant to Pfizer, Astellas, and Janssen. H.Z. declares no competing interests.